ABX-CRO   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dresden Germany (1998)

Organization Overview

First Clinical Trial
2005
NCT00209417
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

ABX CRO | ABX-CRO/Medifacts GmbH

Active Ingredients

Drugs in Phase 4 Trials (2)

iodixanol (visipaque) (1 trial)

iopamidol (Isovue) (1 trial)

Drugs in Phase 3 Trials (3)

amino acids (Freamine) (1 trial)

everolimus (zortress) (1 trial)

lutetium dotatate lu-177 (Lutathera) (1 trial)

Drugs in Phase 2 Trials (1)

Ga 68 PSMA-11 (Illuccix) (1 trial)

Drugs in Phase 1 Trials (2)

cor-1 (1 trial)

revacept (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 1)

Heart Failure (Phase 1)

Infarction (Phase 1)

Myocardial Infarction (Phase 1)

Neoplasm Metastasis (Phase 2)

Neuroendocrine Tumors (Phase 3)

Prostatic Neoplasms (Phase 2)

Renal Insufficiency (Phase 4)

Thrombosis (Phase 1)

Tissue Adhesions (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8